PurTTM
がいいねしました
$ディディ・グローバル (DIDI.US)$私の意見では、これは良い買い物です。14で買った機関投資家が本当にこの株で利益を上げない限り、売却することはありません。今は14-15で買うことができるので、この会社の成長とポテンシャルに比べて非常にお得です。さらに今買うことは、機関投資家が買った14に近い価格で買うことを意味します🙌🏻
翻訳済み
9
2
PurTTM
がいいねしました
PurTTM
コメントしました
$Orphazyme (ORPH.US)$
“We are disheartened by the outcome of the FDA’s review, given the urgent need for a new therapeutic option for NPC, but we remain committed to working with the regulators, with the goal of delivering arimoclomol tofamilies managing this challenging disease,” said CEO Christophe Bourdon. He continued: “We will focus our efforts on pursuing the European regulatory approval, with CHMP opinion expected in Q4 2021 and potential Marketing Authorization in Q1 2022. We are assessing the potential path forward in the U.S. in partnership with the FDA. In the short-term, we will need to reduce our costs substantially and freeze all company efforts not related to clinical and regulatory activities to support approval for NPC.”...
“We are disheartened by the outcome of the FDA’s review, given the urgent need for a new therapeutic option for NPC, but we remain committed to working with the regulators, with the goal of delivering arimoclomol tofamilies managing this challenging disease,” said CEO Christophe Bourdon. He continued: “We will focus our efforts on pursuing the European regulatory approval, with CHMP opinion expected in Q4 2021 and potential Marketing Authorization in Q1 2022. We are assessing the potential path forward in the U.S. in partnership with the FDA. In the short-term, we will need to reduce our costs substantially and freeze all company efforts not related to clinical and regulatory activities to support approval for NPC.”...
1
$AMCエンターテインメント クラスA (AMC.US)$ what time will the show starts tomorrow? 🍿
$Orphazyme (ORPH.US)$ will this be another distraction from AMC?
2